 "Aurelien Breton, managing director, Servier India")
French drugmaker Servier is sharpening its India strategy as it looks to bring more first-in-class and precision medicines into the country, deepen its role in global clinical research, and use India as a hub for manufacturing and global capability centres (GCCs).
The company is targeting a turnover of about ₹1,000 crore from India over the medium term, underscoring the market’s rising importance in its global growth plans.
India currently contributes about 1 per cent to Servier’s global revenue, but that share is set to climb as newer oncology products are launched and the company expands its footprint beyond its legacy
